What is the current valuation of the antibody drug-discovery market in South Korea?

The market valuation was $169.07 Million in 2024. Read More

What is the projected market size for the antibody drug-discovery market by 2035?

The projected valuation for 2035 is $433.67 Million. Read More

What is the expected CAGR for the South Korea antibody drug-discovery market during 2025 - 2035?

The expected CAGR during this period is 8.94%. Read More

Which companies are the key players in the South Korea antibody drug-discovery market?

Key players include Roche, AbbVie, Amgen, Johnson & Johnson, Merck & Co., Novartis, GSK, Bristol-Myers Squibb, and Sanofi. Read More

What are the main types of antibodies in the market, and what were their valuations in 2024?

Monoclonal Antibodies were valued at $80.0 Million, Polyclonal Antibodies at $30.0 Million, Antibody-Drug Conjugates at $40.0 Million, and Bispecific Antibodies at $19.07 Million. Read More

How does recombinant DNA technology compare to other technologies in the market?

Recombinant DNA Technology had a valuation of $30.0 Million, while Hybridoma Technology was valued at $40.0 Million, indicating a competitive landscape. Read More

What are the therapeutic applications of antibodies, and what were their market values in 2024?

Therapeutic Applications were valued at $80.0 Million, Diagnostic Applications at $40.0 Million, and Research Applications at $49.07 Million. Read More

What is the market valuation for pharmaceutical companies involved in antibody drug-discovery?

Pharmaceutical Companies had a valuation of $75.0 Million in 2024. Read More

What role do biotechnology companies play in the antibody drug-discovery market?

Biotechnology Companies were valued at $50.0 Million, highlighting their contribution to the market. Read More

What is the significance of research institutions in the antibody drug-discovery market?

Research Institutions had a valuation of $44.07 Million, indicating their essential role in advancing antibody research. Read More

South Korea Antibody Drug Discovery Market

ID: MRFR/Pharma/50163-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

South Korea Antibody Drug Discovery Market Research Report By Type (Monoclonal Antibodies, Polyclonal Antibodies, Antibody-Drug Conjugates, Bispecific Antibodies), By Technology (Recombinant DNA Technology, Hybridoma Technology, Phage Display Technology, Transgenic Technology), By Application (Therapeutic Applications, Diagnostic Applications, Research Applications) andBy End Use (Pharmaceutical Companies, Biotechnology Companies, Research Institutions) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Monoclonal Antibodies
  2. 4.1.2 Polyclonal Antibodies
  3. 4.1.3 Antibody-Drug Conjugates
  4. 4.1.4 Bispecific Antibodies
2. 4.2 Pharmaceutical, BY Technology (USD Million)
  1. 4.2.1 Recombinant DNA Technology
  2. 4.2.2 Hybridoma Technology
  3. 4.2.3 Phage Display Technology
  4. 4.2.4 Transgenic Technology
3. 4.3 Pharmaceutical, BY Application (USD Million)
  1. 4.3.1 Therapeutic Applications
  2. 4.3.2 Diagnostic Applications
  3. 4.3.3 Research Applications
4. 4.4 Pharmaceutical, BY End Use (USD Million)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Biotechnology Companies
  3. 4.4.3 Research Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 AbbVie (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 GSK (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bristol-Myers Squibb (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TYPE
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY END USE
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USE, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea South Korea Antibody Drug Discovery Market Segmentation

South Korea Antibody Drug Discovery Market By Type (USD Million, 2025-2035)

Monoclonal Antibodies
Polyclonal Antibodies
Antibody-Drug Conjugates
Bispecific Antibodies

South Korea Antibody Drug Discovery Market By Technology (USD Million, 2025-2035)

Recombinant DNA Technology
Hybridoma Technology
Phage Display Technology
Transgenic Technology

South Korea Antibody Drug Discovery Market By Application (USD Million, 2025-2035)

Therapeutic Applications
Diagnostic Applications
Research Applications

South Korea Antibody Drug Discovery Market By End Use (USD Million, 2025-2035)

South Korea Antibody Drug Discovery Market Companies
Biotechnology Companies
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”